FENTANILE is developed by Complexo Hospitalario Universitario de A Coruña.

What development phase is FENTANILE in?

FENTANILE is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

FENTANILE

Complexo Hospitalario Universitario de A Coruña · FDA-approved active Small molecule Quality 4/100

At a glance

Generic name	FENTANILE
Also known as	FENTANILE 0,05 mg/ml ATC N01AH01 MAN 41764
Sponsor	Complexo Hospitalario Universitario de A Coruña
Modality	Small molecule
Therapeutic area	Pain
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Trial to Examine Individual Pain Tolerance in the Use of Two Anesthetic Techniques to Perform Saturation Prostate Biopsy (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

FENTANILE CI brief — competitive landscape report
FENTANILE updates RSS · CI watch RSS
Complexo Hospitalario Universitario de A Coruña portfolio CI